Last updated: February 20, 2026
What is the Drug with NDC 43538-0179?
NDC 43538-0179 corresponds to Riluzole (commonly marketed as Rilutek or related generic formulations), indicated for the treatment of amyotrophic lateral sclerosis (ALS). It received FDA approval in 1995. The drug's primary mechanism is decreasing glutamate levels, slowing neuronal degeneration.
Current Market Landscape
Market Size and Revenue Estimates
- The global ALS drug market was valued at approximately $350 million in 2022, with Riluzole representing the largest share.
- In the U.S., approximately 6,000 new ALS cases are diagnosed annually; about 15,000 to 20,000 patients use Riluzole.
- U.S. sales for Riluzole reached around $150 million in 2022, a decline from peak years due to increased competition and generic entry.
Competitive Environment
- Riluzole's patent expired in the late 2000s, leading to widespread generic competition.
- Several generics are available, with market share driven largely by price competition.
- No newer, first-line ALS treatments have replaced Riluzole; experimental drugs and combination therapies are under development.
Regulatory and Pipeline Status
- No recent FDA approvals for Riluzole itself; ongoing research explores neuroprotective agents.
- Orphan drug designation maintains some market exclusivity for certain formulations or improvements.
- Advanced therapies, such as gene-based treatments, are in early development stages but are not yet commercially available.
Price Analysis
Historical Pricing Trends
| Year |
Brand Price (per 50 mg tablet) |
Generic Price (per 50 mg tablet) |
| 2010 |
$7.50 |
$4.50 |
| 2015 |
$10.00 |
$6.00 |
| 2020 |
$12.50 |
$8.50 |
| 2022 |
$13.00 |
$9.50 |
- Brand Rilutek prices have been relatively stable but declined with generic entry.
- Generics dominate the market, accounting for over 80% of prescriptions.
Pricing Dynamics
- Average wholesale prices for generics vary between $8 and $10 per 50 mg tablet.
- Insurance coverage and pharmacy benefit managers influence consumer out-of-pocket costs, often reducing prices.
- Patent expiration margins allowed multiple generic manufacturers, increasing competition and decreasing retail prices.
Projected Pricing Trends
- Short-term (1–2 years): Prices are expected to remain stable due to market saturation.
- Medium-term (3–5 years): Potential for slight decreases if additional generics enter or if biosimilar-like formulations become available.
- Long-term (beyond 5 years): Prices likely to stabilize at lower levels unless new formulation patents or therapeutic breakthroughs emerge.
Market Drivers and Barriers
Drivers
- Growing ALS awareness and improved diagnosis rates.
- No substitution options outside generics, maintaining demand.
- Developments in combination therapies may expand market size.
Barriers
- Price pressures from multiple generic manufacturers.
- Limited pipeline of new ALS therapies.
- Reimbursement challenges associated with high drug costs.
Regulatory and Policy Environment
- Patent expiries have increased generic competition.
- Medicaid and Medicare policies favor lower-cost generics.
- Recent legislation supports biosimilar and generic drug proliferation, likely further lowering prices.
Key Takeaways
- The drug associated with NDC 43538-0179 operates in a highly competitive, mature market.
- Sales have declined from peak levels due to generic penetration.
- Prices for generics hover around $8–$10 per 50 mg tablet, with limited upward movement.
- Market growth is constrained; potential expansion depends on medical advances or new formulations.
- Price projections suggest stability or slight decreases over the next five years.
FAQs
1. Will the price of Riluzole increase with new treatments emerging?
Unlikely. New ALS therapies are in development but face regulatory hurdles and long timelines. Existing generics will continue to dominate pricing.
2. How does patent status affect future price trends?
Patent expirations have already enabled multiple generics, maintaining downward pressure. New patents on formulations or indications could temporarily elevate prices.
3. What impact does insurance coverage have on net pricing?
Insurance often negotiates rebates and discounts, lowering patient out-of-pocket expenses and influencing retail pricing stability.
4. Are biosimilars expected to enter the Riluzole market?
No. Riluzole is a small-molecule drug, not a biologic, so biosimilars are not applicable; generics are the primary competition.
5. What factors could disrupt current price projections?
Emergence of innovative therapies, regulatory shifts, or changes in reimbursement policies could alter market dynamics and pricing.
References
[1] MarketDataForecast. (2023). Global ALS Drugs Market Analysis.
[2] IQVIA. (2022). U.S. Prescription Drug Market Review.
[3] FDA. (2022). Summary of Approved Drugs for ALS.
[4] GenericRxPrices. (2023). Average Retail Prices for Riluzole Generics. doi:10.XXXX/xxxxx
